Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eysuvis in Dry Eye Disease (STRIDE 1)
NCT02813265Phase 3Completed
- Sponsor
- KALA BIO
- Start
- Jun 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lifitegrast in dry eye disease (DED) (2 arms), sponsored by KALA BIO. Primary endpoints: Change From Baseline in Bulbar Conjunctival Hyperemia at Day 15, Change From Baseline in Ocular Discomfort Severity at Day 15 and 2 more. Started Jun 2016; status: completed.
02
Drugs
lifitegrast
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT02813265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02813265.